Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients.
Westerveld H, de Leeuw A, Kirchheiner K, Dankulchai P, Oosterveld B, Oinam A, Hudej R, Swamidas J, Lindegaard J, Tanderup K, Pötter R, Kirisits C; EMBRACE Collaborative Group. Westerveld H, et al. Among authors: lindegaard j. Radiother Oncol. 2016 Sep;120(3):420-427. doi: 10.1016/j.radonc.2016.05.002. Epub 2016 May 26. Radiother Oncol. 2016. PMID: 27237058
Variation of treatment planning parameters (D90 HR-CTV, D 2cc for OAR) for cervical cancer tandem ring brachytherapy in a multicentre setting: comparison of standard planning and 3D image guided optimisation based on a joint protocol for dose-volume constraints.
Jürgenliemk-Schulz IM, Lang S, Tanderup K, de Leeuw A, Kirisits C, Lindegaard J, Petric P, Hudej R, Pötter R; Gyn GEC ESTRO network. Jürgenliemk-Schulz IM, et al. Among authors: lindegaard j. Radiother Oncol. 2010 Mar;94(3):339-45. doi: 10.1016/j.radonc.2009.10.011. Epub 2009 Nov 26. Radiother Oncol. 2010. PMID: 19944471
Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer.
Fenkell L, Assenholt M, Nielsen SK, Haie-Meder C, Pötter R, Lindegaard J, Tanderup K. Fenkell L, et al. Among authors: lindegaard j. Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1572-9. doi: 10.1016/j.ijrobp.2010.05.031. Epub 2010 Aug 26. Int J Radiat Oncol Biol Phys. 2011. PMID: 20800373
Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients.
Kirchheiner K, Nout R, Lindegaard J, Petrič P, Limbergen EV, Jürgenliemk-Schulz IM, Haie-Meder C, Pötter R, Dörr W. Kirchheiner K, et al. Among authors: lindegaard j. Strahlenther Onkol. 2012 Oct;188(10):933-9. doi: 10.1007/s00066-012-0156-6. Epub 2012 Aug 17. Strahlenther Onkol. 2012. PMID: 22895624 Clinical Trial.
Assessment of Parametrial Response by Growth Pattern in Patients With International Federation of Gynecology and Obstetrics Stage IIB and IIIB Cervical Cancer: Analysis of Patients From a Prospective, Multicenter Trial (EMBRACE).
Yoshida K, Jastaniyah N, Sturdza A, Lindegaard J, Segedin B, Mahantshetty U, Rai B, Jürgenliemk-Schulz I, Haie-Meder C, Sasaki R, Pötter R. Yoshida K, et al. Among authors: lindegaard j. Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):788-96. doi: 10.1016/j.ijrobp.2015.08.007. Epub 2015 Aug 7. Int J Radiat Oncol Biol Phys. 2015. PMID: 26530747
193 results